These tyrosine kinase receptors have received some attention from the clinical point of view, given that NTRK gene fusions including NTRK1, NTRK2, and NTRK3 are identified as oncogenic drivers in various types of tumors, including an increase in cancer in DM1 [118]. This evidence concerns the gene NTRK3 and myotonic dystrophy type 1.